Annual report pursuant to Section 13 and 15(d)

Business (Details)

v3.20.1
Business (Details)
 3 Months Ended 12 Months Ended
Feb. 06, 2020
USD ($)
$ / shares
shares
Feb. 03, 2020
USD ($)
product
shares
Sep. 04, 2019
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
shares
Sep. 30, 2019
USD ($)
$ / shares
shares
Mar. 31, 2019
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
product
shares
Dec. 31, 2018
USD ($)
Nov. 01, 2019
shares
Subsequent Event [Line Items]                    
Contingent consideration         $ 0     $ 0    
Non-cash gain on sale of Pediatric Portfolio to Aytu               7,964,924 $ 0  
Net (loss) income               (16,072,547) (40,052,810)  
Net cash used in operating activities               (19,134,332) (3,128,102)  
Accumulated deficit         (114,290,617)     (114,290,617) (98,218,070)  
Cash and cash equivalents         3,609,438     $ 3,609,438 $ 10,646,301  
Neurological Clinical And Preclinical Stage Compounds                    
Subsequent Event [Line Items]                    
Number of products in development | product               3    
Underwritten Public Offering                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares             1,818,182      
Sale of stock price per share (in dollars per share) | $ / shares             $ 5.50      
Armistice Purchase Agreement                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares     1,200,000     1,200,000        
Sale of stock price per share (in dollars per share) | $ / shares     $ 3.132     $ 3.132        
Consideration received     $ 3,700,000     $ 3,700,000        
Subsequent Event | Clinical Stage                    
Subsequent Event [Line Items]                    
Number of products in development | product   6                
Subsequent Event | Registered Direct Offering                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares 1,306,282                  
Sale of stock price per share (in dollars per share) | $ / shares $ 3.98                  
Aevi | Subsequent Event                    
Subsequent Event [Line Items]                    
Loan forgiven   $ 4,100,000                
Aevi | Subsequent Event                    
Subsequent Event [Line Items]                    
Shares issued for purchase of business (in shares)   $ 15,600,000                
Consideration issued (in shares) | shares   3,900,000                
Contingent consideration   $ 6,500,000                
Pediatric Portfolio                    
Subsequent Event [Line Items]                    
Proceeds from sale of assets         4,500,000          
Assumption of debt on sale of assets         15,100,000     $ 15,100,000    
Non-cash gain on sale of Pediatric Portfolio to Aytu         8,000,000          
Pediatric Portfolio | AYTU                    
Subsequent Event [Line Items]                    
Liabilities assumed by buyer         $ 11,000,000     $ 11,000,000    
Convertible Preferred Stock | AYTU                    
Subsequent Event [Line Items]                    
Investment, shares (in shares) | shares         9,800,000     9,800,000   9,800,000
Common stock | Underwritten Public Offering                    
Subsequent Event [Line Items]                    
Consideration received             $ 9,000,000      
Common stock | Armistice | Underwritten Public Offering                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares             363,637      
Common stock | Armistice | Subsequent Event | Registered Direct Offering                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares 1,256,282                  
Consideration received $ 5,000,000                  
Scenario, Forecast | Subsequent Event | Registered Direct Offering                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares       1,306,282            
Sale of stock price per share (in dollars per share) | $ / shares       $ 3.98            
Scenario, Forecast | Common stock | Armistice | Subsequent Event | Registered Direct Offering                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares       1,256,282            
Consideration received       $ 5,000,000